The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Commission and the pharmaceutical industry which aims to promote more efficient discovery and development of medicines by supporting research into the drug development process. The IMI is funded equally by the EU and industry and has a budget of EUR 2 billion for the period 2008-2017.
New: 5th Call 2012: Two topics currently under consideration for the first half of 2012
The European Commission has recently published details of two topics being considered for funding in 2012. These are:
- European lead factory: Joint European compound library and screening centre
- Tackling resistance to antibiotics: building partnerships to progress the discovery and development of novel antibiotic drugs to treat the most urgent infections
Please note that at this stage, all information regarding the IMI 5th Call topics is indicative and subject to change. Final information about the IMI 5th Call will be communicated after approval by the IMI Governing Board. Further details will be available here later in 2012. http://www.imi.europa.eu/content/5th-call-2012
The IMI has also recently improved funding and simplified accounting rules for project participants to support this year’s programme. Details may be found here: http://www.imi.europa.eu/
INNOVATIVE MEDICINES INITIATIVE (IMI), 5th CALL: INFODAY
The Innovative Medicines Initiative (IMI) will hold an Open Info Day on its 5th Call for proposals in Brussels, on Monday 27 February 2012.
Further information
For more information on IMI, and the information day, please see the IMI website.